Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001
Stratford-upon-Avon, UK: April, 6 2020 – Celixir, a privately-owned company discovering and developing life-saving advanced therapies, announces an update to its ongoing clinical programme with lead therapeutic candidate CLXR-001. The first patient was successfully dosed in the Company’s Heartcel clinical trial of its novel iMP cells in patients with cardiomyopathy on
March 16, 2020 and is now in the follow up stage. CLXR-001 is a novel formulation that allows for rapid point-of-care use of Celixir’s novel allogeneic (off-the-shelf) iMP cells without the
requirement for a cell culture laboratory.
In consultation with the Medicines and Healthcare products Regulatory Agency (MHRA) and given the suspension of research trials due to the Covid-19 pandemic, Celixir has made the
decision to suspend the current Heartcel clinical trial and replace the current clinical trial application (CTA) with a revised protocol. Recruitment is scheduled to recommence under a new CTA in Q3 2020 ‒ subject to lifting of Covid-19 restrictions ‒ with the study expected to complete in 2021.
Celixir continues to work closely with guidance from the MHRA and the Health Research Authority (HRA) and NHS Research Ethics Committee (REC), all of which reviewed the regulatory dossier prior to granting approval in 2019.
Professor Stephen Westaby, Celixir’s Chief Cardiac Medical Advisor, said: “A 2012 investigator-led trial run by an academic team in Greece importantly showed no adverse effects
and all the patients are still doing well several years later. This was a small study but the outcomes were remarkable. There was a significant reduction of scar tissue in the damaged heart muscle, which conveyed a reduced likelihood of developing heart failure. Our larger, formal clinical trial aims to further investigate this important finding with a new off-the-shelf formulation that can be used quickly, without the need for cell culture. We believe that this treatment has enormous potential to improve the lives of the many millions of patients with cardiomyopathy.”
Professor Sir Martin Evans, Celixir’s Chief Scientific Officer, added: “Heart failure remains a life threatening condition and innovative new treatments are desperately needed. We are pioneering a cellular therapy aimed at progressing the heart regeneration field and which, if the trials prove effective, will itself provide a significant benefit towards recovery. This trial highlights our small company’s important contribution to the field including a novel cell therapy with an off-the-shelf product formulation, GMP manufacturing and UK-approved clinical trial.”
![Celixir Heartcel - Immunomodulatory Progenitor [Imp] Cells](https://d1py1ngsne97dt.cloudfront.net/ew0KICAiYnVja2V0IjogImVlLWZpbGVzIiwNCiAgImtleSI6ICJmaWxlcy8xMTg2OTQvaW1hZ2VzLzExODY5NF8wXzIwMjEwOTAxMDk0NjAwNjEwNzMxMV80MDAucG5nIiwNCiAgImVkaXRzIjogew0KICAgICJyZXNpemUiOiB7DQogICAgICAiZml0IjogImNvbnRhaW4iLA0KICAgICAgImJhY2tncm91bmQiOiB7DQogICAgICAgICJyIjogMjU1LA0KICAgICAgICAiZyI6IDI1NSwNCiAgICAgICAgImIiOiAyNTUsDQogICAgICAgICJhbHBoYSI6IDENCiAgICAgIH0sDQogICAgICAid2lkdGgiOiAxMjIsDQogICAgICAiaGVpZ2h0IjogOTANCiAgICB9DQogIH0NCn0= "Celixir Heartcel - Immunomodulatory Progenitor [Imp] Cells")
Celixir Heartcel - Immunomodulatory Progenitor [Imp] Cells
Related news
-
Artugen Announces Five Abstracts Published in the 30th ECCMID Abstract Book
Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world. Without effective antibiotics and therapeutics for the prevention and treatment of infections, many of the achievements of modern medicine such...
-
Professional Old Age Home Care Services in Australia
JK Home Care is delighted to extend its range of professional home care services in Australia. Transforming home care solutions, the specialized team of qualified experts at JK Home Care offer world-class therapeutic supports, specialized supported employment, specialized positive behavior support, participation in the community, innovative community participation, home modifications and more aligned to the patient’s requirement. JK Home Care was born out of a desire to care and give back to the community....
-
Diaphragm Pacemaker for Teen Featured on WSB-TV Atlanta
Fourteen year-old Sedarius was recently featured on WSB-TV Atlanta as the first pediatric patient to receive surgery to implant a diaphragm pacemaker in the state of Georgia. Sedarius was diagnosed with CCHS when he was eight years old, and required a tracheotomy and ventilator to breathe while he slept. The Avery Breathing Pacemaker will allow him to breathe without the need for a trach or ventilator and help improve his quality of life. He was able to return home within a few days, and it is expected that he...
-
Flat Medical announced FDA 510(k) clearance of EpiFaith, the Epidural Safety Solution
Flat Medical Co., Ltd., the medtech company specializing in clinical safety solutions, announced it received 510(k) clearance from the U.S. Food and Drug Administration for its EpiFaith® syringe to deliver safe epidural locating solution. Based on the LOR technique, the EpiFaith® syringe is a physician-centered safeguard for epidural analgesia, which is indicated for painless labor, surgical anesthesia and chronic pain management. Compared with traditional practice that relies on the manual sense, EpiFaith&...
-
Haymarket Medical Network Launches Rare Disease Advisor
Haymarket Medical Network today launched Rare Disease Advisor, a new digital resource for healthcare professionals (HCPs) to help them recognize, diagnose, refer and treat rare diseases. RareDiseaseAdvisor.com fills an information gap for HCPs by providing difficult to find information on rare diseases in one convenient place, enabling physicians and care teams with a comprehensive digital resource that will empower them to improve patient outcomes. The site’s thorough approach to covering rare disease...
Customer comments
No comments were found for Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001. Be the first to comment!